---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; BAROSTIM NEO"
date: 2026-02-05 19:08:56 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-06210
original_published: 2021-03-25 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; BAROSTIM NEO

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 25, 2021 00:00 UTC
**Document Number:** 2021-06210

## Summary

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAROSTIM NEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/25/2021-06210/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barostim-neo)
- API: https://www.federalregister.gov/api/v1/documents/2021-06210

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
